
|Videos|October 3, 2022
Dr. Wee on androgen receptor inhibitors for the management of nonmetastatic CRPC
Author(s)Urology Times staff
Advertisement
Christopher Wee, MD, a genitourinary medical oncologist at Cleveland Clinic, discusses available androgen receptor inhibitors for the treatment of patients with nonmetastatic castration-resistant prostate cancer, including apalutamide (Erleada) darolutamide (Nubeqa) and enzalutamide (Xtandi). He also explains what is still needed to optimize the use of these agents in this space.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Individualizing androgen pathway therapy in mCSPC
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












